Form 4: Ionis Pharma EVP Acquires Shares via ESPP

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, acquired 376 shares of common stock through an employee stock purchase plan.

Summary

• Patrick R. O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals, Inc. (IONS), acquired 376 shares of common stock.
• The acquisition occurred on February 27, 2026, at a price of $48.8665 per share.
• These shares were purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan.
• Following this transaction, O'Neil directly beneficially owns 72,359 shares of common stock.
• The acquired shares are subject to a restriction and may not be sold until August 27, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as an executive increasing their stake, even through an ESPP, generally indicates confidence in the company's future, though the impact of a relatively small purchase is limited.

Positives

• An executive is increasing their direct ownership in the company, which can signal confidence in the company's future prospects.
• The acquisition was made through an Employee Stock Purchase Plan, often indicating a discounted purchase price and a long-term investment strategy by the employee.

Negatives

• The acquired shares are subject to a six-month lock-up period, meaning they cannot be sold until August 27, 2026.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider's stock transaction.

Industry Context

StockSavvy.ai notes that insider purchases, even through employee plans, are often viewed positively by the market as they can signal management's belief in the company's intrinsic value and future growth, aligning executive interests with those of shareholders. This is a standard transaction for executives participating in an ESPP.

Related Party Transactions

• Patrick R. O'Neil, an executive of Ionis Pharmaceuticals, acquired shares from the company through an employee stock purchase plan, which is a common form of related-party transaction in executive compensation.

Stakeholder Impact

• Shareholders: May view this as a positive signal of management confidence, potentially bolstering investor sentiment.
• Employees: Participation in the ESPP demonstrates the benefits available to employees for investing in the company.

Next Steps

• The acquired shares will become eligible for sale on August 27, 2026.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Patrick R. O'Neil, Insider Trading, Form 4, Stock Purchase, Employee Stock Purchase Plan, Executive Compensation